<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In aggressive non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, the result of <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography (PET) with [<z:chebi fb="0" ids="36939">18F</z:chebi>]fluorodeoxyglucose performed after a few cycles of chemotherapy has been shown to correlate with long-term treatment outcome </plain></SENT>
<SENT sid="1" pm="."><plain>The PETAL trial investigates whether a change in treatment protocol may improve the outcome of patients with a positive scan after two cycles of (R-)CHOP </plain></SENT>
<SENT sid="2" pm="."><plain>Such patients are randomized to receive a further six cycles of (R-)CHOP or six blocks of the <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> protocol, a regimen for the treatment of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Precautions taken to minimize false-positive interim-PET results include adherence to a 3-week interval between chemotherapy and interim-PET scanning, avoidance of hematopoietic growth factors, and SUV-based rather than visual interim-PET assessment </plain></SENT>
<SENT sid="4" pm="."><plain>So far, 175 patients have been enrolled of whom 128 have reached interim-PET scanning </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with a positive scan, relapses were six times more frequent than in patients with a negative scan </plain></SENT>
<SENT sid="6" pm="."><plain>Recruitment into the trial continues </plain></SENT>
</text></document>